-
公开(公告)号：AU2008232409A1
公开(公告)日：2008-10-02
申请号：AU2008232409
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： GARBER ELLEN A , ROBINSON MARTYN KIM , SHOCK ANTHONY , TAYLOR FREDERICK R , BURKLY LINDA C , HSU YEN-MING , FERRANT-ORGETTAS JANINE L , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , SU LIHE , ADAMS RALPH , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：AT395083T
公开(公告)日：2008-05-15
申请号：AT04798568
申请日：2004-11-16
Applicant: UCB PHARMA SA
Inventor： CHRISTIE MARK IAN , MEAD RICHARD JAMES , ROBINSON MARTYN KIM , RAPECKI STEPHEN EDWARD
IPC: A61K39/395 , A61K47/48 , A61P37/00 , C07K16/24
-
公开(公告)号：NO20076046A
公开(公告)日：2008-01-30
申请号：NO20076046
申请日：2007-11-23
Applicant: UCB PHARMA SA
Inventor： LATHAM JOHN , PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LAWSON ALASTAIR , LU HSIENG SEN , POPPLEWELL ANDY , SHEN WENYAN , WINKLER DAVID , WINTERS AARON GEORGE
IPC: C07K14/51 , C07K14/435 , C07K16/18 , C07K16/28
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , C07K14/76 , C07K14/79 , C07K16/18 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
-
公开(公告)号：ES2902548T3
公开(公告)日：2022-03-28
申请号：ES19211623
申请日：2006-04-28
Applicant: UCB PHARMA SA , AMGEN INC
Inventor： PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMAN KELLY SUE , LATHAM JOHN , LAWSON ALASTAIR , LU HSIENG SEN , POPPLEWELL ANDY , SHEN WENYAN , WINKLER DAVID , WINTERS AARON GEORGE
Abstract: Un anticuerpo monoclonal que se une a esclerostina humana; aumenta al menos uno de formación de hueso, densidad mineral ósea, contenido mineral óseo, masa ósea, calidad ósea y fuerza ósea en un mamífero; y se une a una parte de la esclerostina humana que consiste en los aminoácidos 51-64, 73-90, 101-117 y 138-149 de la SEQ ID NO: 1, en donde dicha parte tiene las tres de: (a) un enlace disulfuro entre los aminoácidos 57 y 111; (b) un enlace disulfuro entre los aminoácidos 82 y 142; y (c) un enlace disulfuro entre los aminoácidos 86 y 144.
-
公开(公告)号：SI3670528T1
公开(公告)日：2022-01-31
申请号：SI200632414
申请日：2006-04-28
Applicant: UCB PHARMA SA , AMGEN INC
-
Patent Agency Ranking
公开(公告)号：NO345294B1
公开(公告)日：2020-11-30
申请号：NO20076046
申请日：2007-11-23
Applicant: AMGEN INC , UCB PHARMA SA
Inventor： LATHAM JOHN , PASZTY CHRISTOPHER , ROBINSON MARTYN KIM , GRAHAM KEVIN , HENRY ALISTAIR JAMES , HOFFMANN KELLY SUE , LAWSON ALASTAIR , LU HSIENG SEN , POPPLEWELL ANDY , SHEN WENYAN , WINKLER DAVID , WINTERS AARON GEORGE
IPC: A61K39/395 , A61P19/08 , A61P19/10
-
公开(公告)号：EA019636B1
公开(公告)日：2014-05-30
申请号：EA200970879
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Изобретениеотноситсяк связывающимбелкам, включающимантитела, производныеантители фрагментыантител, которыеспецифическисвязываютсяс белком CD154 (CD40L). Такжеданноеизобретениеотноситсяк химерному, гуманизированномуилиполностьючеловеческомуантителу, производномуантителаи фрагментуантитела, которыеспецифическисвязываютсяс эпитопом, скоторымспецифическисвязываетсягуманизированныйфрагмент Fab, содержащийпоследовательностьвариабельнойобластитяжелойцепи SEQ ID NO: 1 исодержащийпоследовательностьвариабельнойобластилегкойцепи SEQ ID NO: 2. CD154-связывающиебелкиподанномуизобретениюмогутпроявлятьпониженнуюэффекторнуюфункциюпосравнениюсовторыманти-CD154-антителом. CD154-связывающиебелкиподанномуизобретениюмогутбытьпригоднымидлядиагностическихи терапевтическихспособов, напримерприлечениии профилактикезаболеваний, втомчислетаковых, которыевключаютнежелательныеиммунныереакции, опосредуемыевзаимодействиями CD154-CD40.
-
公开(公告)号：SG196697A1
公开(公告)日：2014-02-13
申请号：SG2012055786
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: - 126 - Abstract BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODYDERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 ANDUSES THEREOF This invention provides binding proteins, includingantibodies, antibody derivatives and antibody fragments, thatspecifically bind a CD 154 (CD4OL) protein. This invention alsoprovides a chimeric, humanized or fully human antibody, antibodyderivative or antibody fragment that specifically binds to an epitopeto which a humanized Fab fragment comprising a variable heavy chainsequence according to SEQ ID NO: 1 and comprising a variable lightchain sequence according to SEQ ID NO: 2 specifically binds. CD154binding proteins of this invention may elicit reduced effectorfunction relative to a second anti-CD154 antibody. CD154 bindingproteins of this invention are useful in diagnostic and therapeuticmethods, such as in the treatment and prevention of diseasesincluding those that involve undesirable immune responses that aremediated by CD154-CD40 interactions. Fig. 19
-
公开(公告)号：AU2012238247A1
公开(公告)日：2012-11-01
申请号：AU2012238247
申请日：2012-10-08
Applicant: AMGEN INC , UCB PHARMA SA
Inventor： WINTERS AARON GEORGE , LAWSON ALASTAIR , HENRY ALISTAIR JAMES , POPPLEWELL ANDY , PASZTY CHRISTOPHER , SHEN WENYAN , LU HSIENG SEN , LATHAM JOHN , HOFFMANN KELLY SUE , GRAHAM KEVIN , ROBINSON MARTYN KIM , WINKLER DAVID
Abstract: C:\NRPorbl\DCCSZPWA6573 I DOC.4/10/2012 Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. 4v Lu L % 6 Iii cc ~ O O. . .U te,, Lo~ .CD C; L 0ZDB aweI
-
公开(公告)号：NZ580245A
公开(公告)日：2012-01-12
申请号：NZ58024508
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: An anti-CD154 antibody that comprises the heavy chain CDR1, CDR2 and CDR3 sequence SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively and the light chain CDR1, CDR2 and CDR3 sequences SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8 respectively. Also disclosed are methods of the production of the antibody and uses thereof for treating rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, inflammatory bowel disease, Crohn's disease, psoriasis, scleroderma and multiple sclerosis.
-
-
-
-
-
-
-
-
-
Search Results
66
records
(took 0.022 seconds)
